Second generation patents in pharmaceutical innovation
By: Hyewon Ahn
Contributors: Munich Intellectual Property Law Center
Edition: 1. edition.
Series: MIPLC studies -- volume 19; MIPLC studies -- v. 19.
Publisher: Nomos
Published: 2014
Place of publication: Baden-Baden
Language: eng
Number of pages: 354
ISBN-13: 9783848708741
Copyright date: 2014
Subjects: Drugs; Drug development; Patent laws and legislation; Law and legislation; Patents
Description: "The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, mainly to produce the information that meets high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks. This is one of the reasons the pharmaceutical industry depends greatly on patent protection. Despite the existing patent system, however, the number of new medications per year has decreased, especially during the last decade. In comparison, the number of second generation patents and products has been drastically increased. The pharmaceutical industry is accused both of neglecting its real mission of providing new medications, while generating second generation products, and of preventing the entry of generics. This book reviews whether the concerns are justified, and, if so, whether or how the patent system can improve the situation that confronts pharmaceutical companies and society"--Publisher's website.
Notes: Originally presented as the author's thesis (doctoral)--University of Augsburg, 2013.

"Munich Intellectual Property Law Center, Augsburg, München, Washington DC."

Includes bibliographical references (pages 333-354).